Galera Therapeutics, Inc.: operating cash flow

What this measure means

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Exact concept: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2018-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• Galera Therapeutics, Inc.: total assets
• Galera Therapeutics, Inc.: total liabilities
• Galera Therapeutics, Inc.: stockholders equity
• Galera Therapeutics, Inc.: cash and cash equivalents
• Galera Therapeutics, Inc.: net income or loss
• Galera Therapeutics, Inc.: capital expenditure payments
• Galera Therapeutics, Inc.: financing cash flow
• Galera Therapeutics, Inc.: investing cash flow
• Galera Therapeutics, Inc.: retained earnings or deficit
• Galera Therapeutics, Inc.: basic weighted-average shares
• Galera Therapeutics, Inc.: diluted weighted-average shares
• Galera Therapeutics, Inc.: basic earnings per share
• Galera Therapeutics, Inc.: diluted earnings per share
• Galera Therapeutics, Inc.: income tax expense or benefit
• Galera Therapeutics, Inc.: net property, plant and equipment
• Galera Therapeutics, Inc.: share-based compensation expense
• Galera Therapeutics, Inc.: operating income or loss
• Galera Therapeutics, Inc.: current assets
• Galera Therapeutics, Inc.: interest expense
• Galera Therapeutics, Inc.: current liabilities
• Galera Therapeutics, Inc.: current accounts payable
• Galera Therapeutics, Inc.: goodwill carrying amount
• Galera Therapeutics, Inc.: research and development expense
• Galera Therapeutics, Inc.: common shares outstanding
• Galera Therapeutics, Inc.: cash including restricted cash
• Galera Therapeutics, Inc.: accumulated other comprehensive income or loss
• Galera Therapeutics, Inc.: operating lease right-of-use asset
• Galera Therapeutics, Inc.: operating lease liability
• Galera Therapeutics, Inc.: gross property, plant and equipment
• Galera Therapeutics, Inc.: accumulated depreciation on property, plant and equipment
• Galera Therapeutics, Inc.: other noncurrent assets
• Galera Therapeutics, Inc.: accrued current liabilities
• Galera Therapeutics, Inc.: prepaid expenses and other current assets
• Galera Therapeutics, Inc.: net deferred tax assets
• Galera Therapeutics, Inc.: pre-tax income or loss from continuing operations
• Galera Therapeutics, Inc.: profit or loss including noncontrolling interests
• Galera Therapeutics, Inc.: comprehensive income or loss
• Galera Therapeutics, Inc.: net income available to common stockholders
• Galera Therapeutics, Inc.: general and administrative expense
• Galera Therapeutics, Inc.: depreciation expense
• Galera Therapeutics, Inc.: depreciation, depletion and amortization
• Galera Therapeutics, Inc.: deferred income tax expense or benefit
• Galera Therapeutics, Inc.: operating lease payments
• Galera Therapeutics, Inc.: change in accounts payable

Inspect the source

Entity

Galera Therapeutics, Inc. / CIK 0001563577

Captured

2026-09-21T17:19:59.873Z

SEC response SHA-256

783b42a433cc8bb61f58be25758fc5bce088fcc5aee9106d0fa692e3838b2b41

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001563577.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))